Acadian Asset Management
WINT

Acadian Asset Management’s Windtree Therapeutics WINT Stock Holding History

Acadian Asset Management’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35
Closed -$39K – 1872
2023
Q2 		$39K Buy
+35
New +$71.1K ﹤0.01% 1559

Other funds holding WINT

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's WINT Position: Q3 2023 in Review

Acadian Asset Management sold out of Windtree Therapeutics (WINT) in Q3 2023, closing a stake of 35 shares — an estimated $39K sold.

Acadian Asset Management first reported a position in WINT in Q2 2023 and held it in 1 quarter. The position peaked at $39K in Q2 2023. 5 funds tracked by Wall St. Rank hold WINT as of Q3 2023.

  • Acadian Asset Management reported no remaining Windtree Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Acadian Asset Management sold 35 Windtree Therapeutics shares in Q3 2023, an estimated $39K.
  • Acadian Asset Management first reported a position in Windtree Therapeutics in Q2 2023 and held it in 1 quarter.
  • Acadian Asset Management's Windtree Therapeutics position peaked at $39K in Q2 2023.
  • 5 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.